RxDoctor Payments Data

Jaspreet Parihar, MD

Urology · Tacoma, WANPI 1447563317

Payments from drug & device makers

$4,587in general payments, 2019–2025

Across 48 payments — averaging $95.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$2K
  • Intuitive Surgical$2K
  • Teleflex LLC$402
  • Astellas Pharma US Inc$188
  • BK Medical Holding Company Inc.$175
  • Amgen$101
  • plus $371 from 9 others

What the payments were for

  • Travel & lodging$2,16147%
  • Food & beverage$1,69737%
  • Education$72916%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neotract Inc.11$1,718
Intuitive Surgical10$1,633
Teleflex LLC5$402
Astellas Pharma US Inc6$188
BK Medical Holding Company Inc.1$175
Amgen2$101
Cook Medical LLC1$81
Coloplast1$76
Johnson & Johnson3$61
Boston Scientific2$37
Acell, Inc.1$36
Dornier Medtech America, Inc2$29
Eisai Inc.1$19
C. R. Bard, Inc. & Subsidiaries1$16
Sagent Pharmaceuticals1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,587 in reported general payments places this provider in the 65th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$155,864
Medicare patients
323
Services billed
1,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron74$51,212
Oxybutynin Chloride ErOxybutynin Chloride190$3,213
Tamsulosin Hcl244$3,093
Finasteride129$1,564
Tolterodine Tartrate19$1,430
Tolterodine Tartrate ErTolterodine Tartrate16$1,314
Methenamine Hippurate11$1,306
Solifenacin Succinate32$1,190
Trospium Chloride19$1,150
Oxybutynin Chloride41$782
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen70$358
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim111$346
Alfuzosin Hcl ErAlfuzosin Hcl22$336
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$192
Levofloxacin31$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$188$51,21274 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 274 urology providers in Washington.

Other urology in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →